Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest Income - NetInterest Income - TotalNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Serina Therapeutics (SER) Cost of Revenue (2018 - 2023)

Serina Therapeutics' Cost of Revenue history spans 6 years, with the latest figure at $1000.0 for Q4 2023.

  • For Q4 2023, Cost of Revenue changed 0.0% year-over-year to $1000.0; the TTM value through Dec 2023 reached $40000.0, up 207.69%, while the annual FY2023 figure was $40000.0, 207.69% up from the prior year.
  • Cost of Revenue for Q4 2023 was $1000.0 at Serina Therapeutics, down from $33000.0 in the prior quarter.
  • Across five years, Cost of Revenue topped out at $79000.0 in Q4 2019 and bottomed at -$94000.0 in Q4 2020.
  • The 5-year median for Cost of Revenue is $4000.0 (2020), against an average of $12150.0.
  • The largest annual shift saw Cost of Revenue skyrocketed 1325.0% in 2019 before it plummeted 218.99% in 2020.
  • A 5-year view of Cost of Revenue shows it stood at $79000.0 in 2019, then tumbled by 218.99% to -$94000.0 in 2020, then skyrocketed by 101.06% to $1000.0 in 2021, then changed by 0.0% to $1000.0 in 2022, then changed by 0.0% to $1000.0 in 2023.
  • Per Business Quant, the three most recent readings for SER's Cost of Revenue are $1000.0 (Q4 2023), $33000.0 (Q3 2023), and $5000.0 (Q2 2023).